About
Unlocking gene control mechanisms to develop small molecule therapies
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Team (22)
Alan Ezekowitz
Board Member
Fulcrum Therapeutics
team_member
Alan Musso
Chief Financial Officer
Fulcrum Therapeutics
team_memberexecutive
Alex C
President and Chief Executive Officer, Board Member
Fulcrum Therapeutics
team_memberexecutive
Bobby Riehle
Vice President, Head of Program Strategy
Fulcrum Therapeutics
team_memberexecutive
Bradley E
Professor of Pathology, Massachusetts General Hospital and Harvard Medical School
Fulcrum Therapeutics
team_member
Colin Hill
Board Member
Fulcrum Therapeutics
team_member
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
8
As Collaborator
0
Total Enrollment
679
By Phase
PHASE3: 2PHASE1: 3PHASE2: 3
By Status
TERMINATED: 4COMPLETED: 3RECRUITING: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT05397470Lead Sponsor
Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
PHASE3Terminated
260 participants
Started: Jun 16, 2022 · Completed: Nov 19, 2024
NCT05169580Lead Sponsor
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
PHASE1Recruiting
70 participants
Started: Dec 13, 2021 · Completed: Dec 31, 2025
NCT05002231Lead Sponsor
Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets
PHASE1Completed
18 participants
Started: Aug 19, 2021 · Completed: Oct 22, 2021
NCT04586985Lead Sponsor
Safety, Tolerability and Pharmacokinetics of FTX-6058
PHASE1Completed
109 participants
Started: Oct 26, 2020 · Completed: Nov 15, 2022
NCT04511819Lead Sponsor
Losmapimod Safety and Efficacy in COVID-19
PHASE3Terminated
52 participants
Started: Aug 28, 2020 · Completed: Mar 31, 2021
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...